|
Pitolisant Offers Important Risk-Benefit Profile for Patients With Narcolepsy
|
|
Pitolisant, a selective histamine 3 receptor antagonist/inverse agonist developed by Harmony Biosciences, was recently approved under the brand name Wakix for the treatment of excessive daytime sleepiness in adults with narcolepsy. |
|
Read more
|
|
|
| FDA Rejects Duchenne Muscular Dystrophy Drug Golodirsen, Citing Safety Concerns |
|
The FDA has issued a complete response letter to Sarepta Therapeutics for its new drug application (NDA) for golodirsen, previously known as SRP-4053, to treat Duchenne muscular dystrophy. |
|
Read more
|
|
|
